Articles from Hologic, Inc.

Women’s cancer testing has declined globally, according to the latest Hologic Global Women’s Health Index, one of the largest collections of data on women’s health and well-being.

Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 28, 2024.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 1:30 p.m. Pacific Time.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2025 on Wednesday, February 5, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women’s health, for approximately $350 million.

Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to develop analyte specific reagents (ASRs) — the “active ingredients” of laboratory-developed tests used to identify specific diseases or conditions — that would aid in the detection of H5N1 bird flu.

Hologic, Inc., (Nasdaq: HOLX) a global leader in women’s health focused on developing innovative medical technologies that effectively detect, diagnose and treat health conditions, today issued the following statement regarding the United States Preventive Services Task Force draft guidelines for cervical cancer screening:

Hologic, Inc. (Nasdaq: HOLX) announced today that Martin Madaus has been elected to the Company’s Board of Directors, effective December 6, 2024. Dr. Madaus was also appointed to the Compensation Committee and the Nominating and Corporate Governance Committee effective December 6, 2024.

Four new studies regarding the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). Among these studies, initial data will be premiered investigating the potential role of the BCI test to identify postmenopausal women with hormone-receptor positive (HR+), early-stage, node-negative disease who are at minimal risk of experiencing a distant recurrence. Full results will be shared during Poster Session 1 on December 11, 2024, at 12:30 p.m. CT [#P1-09-13].

Hologic, Inc. (Nasdaq: HOLX) yesterday presented new research demonstrating the performance of its Genius AI® Detection 2.0 software across diverse patient populations at the 110th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA).

Hologic, Inc. (Nasdaq: HOLX) will reveal new technologies reimagining the future of breast health at the 110th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago on December 1-5. On the show floor and during multiple workshops, Hologic will showcase AI-powered breast imaging advancements designed to assess breast density, enhance workflows and improve cancer detection.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 28, 2024.

Hologic, Inc. (Nasdaq: HOLX), a global champion of women’s health, today announced that it has signed a definitive agreement to acquire Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women’s health for approximately $350 million, subject to working capital and other customary closing adjustments.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2024 on Monday, November 4, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, will kick off Breast Cancer Awareness Month by ringing the Nasdaq opening bell for the 18th year. As part of this annual tradition, Hologic is launching a comprehensive patient education campaign to bust common myths about breast cancer, mammograms and breast density.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5th, at 12:20 p.m. Eastern Time.

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 29, 2024.

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Endomagnetics Ltd (Endomag), a privately held UK-based developer of breast cancer surgery technologies, for approximately $310 million.

Millions of women in the United States have missed screenings for serious, often life-threatening conditions, according to a new survey released today by women’s health innovator Hologic, Inc. (Nasdaq: HOLX).

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2024 on Monday, July 29, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 30, 2024.

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced that it signed a definitive agreement to acquire Endomagnetics Ltd (Endomag®), a privately held developer of breast cancer surgery technologies, for approximately $310 million, subject to working capital and other customary closing adjustments.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2024 on Thursday, May 2, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced newly published study results revealing that use of the Breast Cancer Index® (BCI) test led to physicians changing their long-term anti-estrogen treatment recommendations for 40% of patients with early-stage hormone receptor-positive (HR+) breast cancer.1 The results, which suggest that many women may be over- or undertreated without the incorporation of BCI, reflect real-world data from the largest prospective study assessing the impact of the BCI test on treatment decisions. The study was published in the March issue of the JNCCN — Journal of the National Comprehensive Cancer Network.

Hologic, Inc. (Nasdaq: HOLX) continues to deliver on its commitment to advancing women’s health by unveiling new research in artificial intelligence (AI) and offering innovative educational opportunities at the annual European Congress of Radiology (ECR) in Vienna, Austria from February 28 to March 2.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:

Hologic, Inc. (Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System with the Genius™ Cervical AI algorithm has received clearance from the U.S. Food and Drug Administration (FDA), making it the first and only FDA-cleared digital cytology system that combines deep-learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells.

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 30, 2023.

The world faces an emergency in women’s health even as the COVID-19 pandemic wanes, according to one of the largest annual updates on women’s well-being — the Hologic Global Women’s Health Index.

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced its new uterine health education and awareness campaign Better is Possible™. Launching in New York, Los Angeles, Atlanta and Detroit, the campaign seeks to increase awareness about daily quality-of-life challenges such as heavy and disruptive periods, pelvic pain and fibroids, while also educating women about available treatment options.

Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 30, 2023.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2024 on Thursday, February 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. Pacific Time.

Hologic, Inc. (Nasdaq: HOLX) will showcase several recent developments in next-generation AI solutions at the 109th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 26 to 30. On the show floor and during multiple workshops, the global leader in breast imaging will unveil advances that leverage AI to improve cancer detection, workflow and patient satisfaction.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 2:10 p.m. Eastern Time.

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 30, 2023.

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced an innovative new partnership with the American Association of Gynecologic Laparoscopists (AAGL) and Inovus Medical. Hologic becomes the chief provider of hysteroscopes for AAGL’s Essentials in Minimally Invasive Gynecologic Surgery (EMIGS) hands-on hysteroscopy skills training for OB-GYN residents.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2023 on Thursday, November 9, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced a series of activities promoting the importance of breast cancer screenings throughout Breast Cancer Awareness Month, including a global partnership with Know Your Lemons, a nonprofit organization committed to improving early detection of breast cancer worldwide through creative and empowering education. To kick off the month, Hologic Chairman, President and CEO Steve MacMillan will ring the Nasdaq opening bell on Monday, October 2, with Hologic employees as well as tennis legend and two-time breast cancer survivor Martina Navratilova.

Hologic, Inc. (Nasdaq: HOLX) announced today that Nanaz Mohtashami has been elected to the Company’s Board of Directors, effective September 20, 2023. Ms. Mohtashami was also appointed to the Compensation Committee and the Nominating and Corporate Governance Committee effective September 20, 2023.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended July 1, 2023.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2023 on Monday, July 31, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the BofA Securities 2023 Healthcare Conference in Las Vegas, NV on Tuesday, May 9 at 2:20 p.m. Pacific Time.

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended April 1, 2023.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2023 on Monday, May 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7 at 9:10 a.m. Eastern Time (E.T.)

Hologic, Inc. (Nasdaq: HOLX) announced today the publishing of “Making a World of Difference,” its latest annual report detailing the company’s sustainability strategy and achievements.

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 31, 2022.

Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 31, 2022.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2023 on Wednesday, February 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. Pacific Time.

Hologic, Inc. (Nasdaq: HOLX) announced today that Stacey D. Stewart has been elected to the Company’s Board of Directors, effective January 2, 2023. Ms. Stewart was also appointed to the Audit and Finance Committee effective January 2, 2023.

Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced new study data showing that the Breast Cancer Index test identified which premenopausal patients with early-stage, hormone-receptor positive (HR+) breast cancer benefited from the addition of ovarian function suppression (OFS) to primary adjuvant endocrine therapy. The Breast Cancer Index test is the first biomarker to be evaluated in a cohort from the landmark Suppression of Ovarian Function Trial (SOFT). The translational study results are featured in the official press program at the 2022 San Antonio Breast Cancer Symposium (SABCS) being held from December 6-10, 2022.1 Full study results were presented during the general session #GS1-06 on December 6 at 3:15 p.m. CST.

Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, swept the 2022 IMV ServiceTrak™ Awards for Mammography, taking home awards for Best Service, Best Customer Satisfaction and Best System Performance. This is the 10th consecutive year that Hologic has ranked first in the industry for Mammography System Performance and Customer Satisfaction and the eighth year for Mammography Service.

Hologic, Inc. (Nasdaq: HOLX) will exhibit its extensive portfolio of breast and skeletal health products at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 27 to Dec. 1. Among the full suite of breast biopsy and surgery solutions will be Hologic’s Affirm® Contrast Biopsy software, which will be on display for the first time since becoming commercially available in the United States.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present virtually at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 2:40 p.m. Eastern Time.

Hologic, Inc. (Nasdaq: HOLX) announced today that it has been awarded a $19 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to support research and development efforts. This funding will help to bring Hologic’s Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and Aptima® SARS-CoV-2 assay in line with the U.S. Food and Drug Administration’s (FDA) in vitro diagnostic (IVD) standards.

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 24, 2022.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2022 on Monday, October 31, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Hologic, Inc. Chairman, President and CEO Steve MacMillan will ring the Nasdaq opening bell today to mark the beginning of Breast Cancer Awareness Month. This is the 16th time that Hologic (Nasdaq: HOLX), an innovative medical technology company and the pioneer of 3D mammography, will ring the bell to raise awareness about breast cancer.

More than 1.5 billion women worldwide lack screenings for cancer, heart disease, diabetes or sexually transmitted diseases/infections – even though these conditions together affect billions of women. The finding comes from one of the world’s largest studies of women’s well-being: the second annual Hologic Global Women’s Health Index.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming investor conferences:

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, and Grammy award-winning and Oscar-nominated artist, producer, and entrepreneur Mary J. Blige today announced the launch of the “Good Morning Gorgeous” sweepstakes. The sweepstakes is an element of Hologic’s role as presenting sponsor of Blige’s “Good Morning Gorgeous” tour, which is presented in partnership with The Black Promoters Collective (BPC) and will take place September 17 through October 29, 2022.

Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a 2018 district court ruling that barred Minerva from challenging the validity of the patent rights it assigned to Hologic.

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 25, 2022.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2022 on Wednesday, July 27, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

A new survey commissioned by Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, revealed a lack of awareness among U.S. women about uterine health, including uterine fibroid symptoms and treatment options. Today, in conjunction with the start of Fibroid Awareness Month, Hologic is proud to announce the launch of Hey, U!, an educational campaign focused on uterine health.

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that Board of Director's member, Sally W. Crawford, has been recognized by the National Association of Corporate Directors (NACD) as part of its 2022 NACD Directorship 100™ — honoring the most influential peer-nominated leaders in the boardroom and corporate governance community.

Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) approved its Aptima CMV Quant assay to quantify the viral load of cytomegalovirus (CMV) in patients who have had solid organ or stem cell transplants. The test is the first to be introduced in the U.S. by Hologic for post-transplant pathogen detection and monitoring on Hologic’s fully automated Panther® system, and joins the existing portfolio of diagnostic and viral load testing for HIV-1, Hepatitis C and Hepatitis B.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 26, 2022.

Hologic, Inc. (Nasdaq: HOLX) announced today that the American Society of Clinical Oncology (ASCO) has published an update which expands the utility of Breast Cancer Index™ (BCI) within its Clinical Practice Guideline: “Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer.” Specifically, ASCO now recognizes BCI as the only genomic test to help guide extended endocrine therapy decisions in early-stage, HR+ breast cancer patients with node negative or node positive (one-three positive nodes) disease when treated with five years of primary endocrine therapy without evidence of recurrence. A special article highlighting the new ASCO guidelines was recently published in the Journal of Clinical Oncology on this subject.1